Innovative Roswell Park Radiation Therapy Protocol in Lung Cancer to Be Highlighted at ASTRO Annual Meeting

Dr. Mark Farrugia to present research cited among most clinically relevant studies at international conference

BUFFALO, N.Y. — Experts from Roswell Park Comprehensive Cancer Center will share the findings of a novel approach using radiation therapy to treat lung cancer at the American Society for Radiation Oncology (ASTRO) Annual Meeting Sept. 27-Oct. 1, 2025, in San Francisco. First author Mark Farrugia, MD, PhD, Clinical Assistant Professor of Oncology in Roswell Park’s Department of Radiation Medicine, will present an oral abstract of a study evaluating a new approach to delivering radiation therapy post-surgery in patients with non-small cell lung cancer (NSCLC). The study will also be included in an ASTRO Science Highlights Session featuring top-rated abstracts.

Led by senior author Anurag Singh, MD, Professor of Oncology and Director of Radiation Research at Roswell Park, the study reports the findings of a single-arm, prospective clinical trial at Roswell Park.

Presentation details:

Abstract 272: “A Feasibility and Toxicity Analysis of Single-Fraction Stereotactic Body Radiation Therapy for Post-Operative Non-Small Cell Lung Cancer”

• Science Highlights Session: Sunday, Sept. 28, 8-8:30 a.m. PT, room 160
• Oral abstract presentation: Monday, Sept. 29, 5:40-5:50 p.m. PT, room 155/157

 

Two Roswell Park posters will be presented Monday, Sept. 29:

• Neil Almeida, MD, of the University at Buffalo and Roswell Park, Resident Physician in Roswell Park’s Department of Radiation Medicine, is first/presenting author of “Early Initiation of Radiation Therapy Improves Survival in Elderly Patients with Glioblastoma” (Abstract 2558), 8-9 a.m. PT, in Hall F. Dheerendra Prasad, MD, MCh, FACRO, Professor of Radiation Medicine, Chief of Gamma Knife Radiosurgery and Medical Director of the Department of Radiation Medicine at Roswell Park, is senior author of the study.
• Singh is senior author on “Association of Systemic Inflammation Response Index with Outcomes among Patients with Head and Neck Cancer Receiving Definitive Chemoradiation” (Abstract 2704), to be presented 10:45 a.m.-noon PT, in Hall F.

###
 

From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. The Roswell Park team of 4,000+ makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Rated “Exceptional” by the National Cancer Institute, Roswell Park, founded in 1898, was one of the first NCI-designated comprehensive cancer centers in the country and remains the only one in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email ASKRoswell@RoswellPark.org.